View in EDS

Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.

Saved in:
Bibliographic Details
Title: Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.
Authors: Propper, D.1, Davidenko, I.2, Bridgewater, J.3, Kupcinskas, L.4, Fittipaldo, A.5, Hillenbach, C.6, Klughammer, B.6, Ducreux, M.7
Source: Annals of Oncology. Jul2014, Vol. 25 Issue 7, p1384-1390. 7p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 96855375
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Propper%2C+D%2E%22">Propper, D.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Davidenko%2C+I%2E%22">Davidenko, I.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Bridgewater%2C+J%2E%22">Bridgewater, J.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Kupcinskas%2C+L%2E%22">Kupcinskas, L.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Fittipaldo%2C+A%2E%22">Fittipaldo, A.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Hillenbach%2C+C%2E%22">Hillenbach, C.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Klughammer%2C+B%2E%22">Klughammer, B.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Ducreux%2C+M%2E%22">Ducreux, M.</searchLink><relatesTo>7</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. Jul2014, Vol. 25 Issue 7, p1384-1390. 7p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=96855375
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/annonc/mdu176
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 1384
    Titles:
      – TitleFull: Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Propper, D.
      – PersonEntity:
          Name:
            NameFull: Davidenko, I.
      – PersonEntity:
          Name:
            NameFull: Bridgewater, J.
      – PersonEntity:
          Name:
            NameFull: Kupcinskas, L.
      – PersonEntity:
          Name:
            NameFull: Fittipaldo, A.
      – PersonEntity:
          Name:
            NameFull: Hillenbach, C.
      – PersonEntity:
          Name:
            NameFull: Klughammer, B.
      – PersonEntity:
          Name:
            NameFull: Ducreux, M.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: Jul2014
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1